Free Trial
NASDAQ:EPRX

Eupraxia Pharmaceuticals 5/6/2025 Earnings Report

Eupraxia Pharmaceuticals logo
$4.32 +0.08 (+1.89%)
Closing price 06/20/2025 03:59 PM Eastern
Extended Trading
$4.36 +0.04 (+1.04%)
As of 06/20/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eupraxia Pharmaceuticals EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.19
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Eupraxia Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eupraxia Pharmaceuticals Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Eupraxia Pharmaceuticals' next earnings date is estimated for Wednesday, August 6, 2025, based on past reporting schedules.

Conference Call Resources

Eupraxia Pharmaceuticals Earnings Headlines

Utah’s New Oil Find
The Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle of the Utah's Black Desert. Why? Not for oil discovery. Or uranium or solar. Instead, what’s happening beneath this patch of sand is the discovery of a new kind of energy. Google, Buffett, and a even tech billionaires like Gates, Bezos, and Zuckerberg are grabbing a stake.
See More Eupraxia Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eupraxia Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eupraxia Pharmaceuticals and other key companies, straight to your email.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals (NASDAQ:EPRX) is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

View Eupraxia Pharmaceuticals Profile

More Earnings Resources from MarketBeat